Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Fsd Pharma Inc Cl B
(NQ:
HUGE
)
0.0899
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Fsd Pharma Inc Cl B
< Previous
1
2
3
4
5
6
7
8
Next >
FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023
August 15, 2023
Via
ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) UNBUZZD Definitive Agreement Featured by Investment Pitch Media
August 03, 2023
Via
Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) UNBUZZD Definitive Agreement Featured by Investment Pitch Media
August 03, 2023
Via
Investor Brand Network
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Launch UNBUZZD
August 02, 2023
Via
Investor Brand Network
FSD Pharma Signs Definitive Agreement to Launch UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink
August 02, 2023
Via
ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Arbitration Panel Finding in Syneos Health (NASDAQ: SYNH) Proceeding
July 18, 2023
Via
Investor Brand Network
Exposures
Product Safety
Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201
July 17, 2023
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stock
July 10, 2023
From
FSD Pharma Inc.
Via
Business Wire
FSD Pharma Appoints Zeeshan Saeed as Chief Executive Officer, Anthony Durkacz to Serve as Executive Co-Chairman of the Board of Directors
July 04, 2023
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Shares Results Shareholder Annual General and Special Meeting
June 30, 2023
Via
Investor Brand Network
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
June 30, 2023
From
FSD Pharma Inc.
Via
Business Wire
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) Featured in InvestmentPitch Media Video
June 23, 2023
Via
Investor Brand Network
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Grant Exclusive Rights to Recreational Alcohol Misuse Technology
June 20, 2023
Via
Investor Brand Network
FSD Pharma Announces Agreement to Grant Exclusive Rights to Revolutionary Recreational Alcohol Misuse Technology
June 20, 2023
From
FSD Pharma Inc.
Via
Business Wire
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Board Appointment of Dr. Eric Hoskins
May 25, 2023
Via
Investor Brand Network
FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors
May 25, 2023
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Featured in InvestmentPitch Media Video
May 16, 2023
Via
Investor Brand Network
Exposures
Product Safety
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports Filing of Complaint, Update on Spin-Out Transaction
May 15, 2023
Via
Investor Brand Network
FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution
May 12, 2023
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Secures $2.81M in Cost Awards from Dr. Raza Bokhari
May 11, 2023
Via
Investor Brand Network
FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari
May 11, 2023
From
FSD Pharma Inc.
Via
Business Wire
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Completion of Phase 1 Dosing in MS Clinical Trial
May 10, 2023
Via
Investor Brand Network
FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort
May 10, 2023
From
FSD Pharma Inc.
Via
Business Wire
Sidoti's Micro-Cap Virtual May Conference
May 09, 2023
Via
ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Present at Sidoti Virtual Investor Conference
May 08, 2023
Via
Investor Brand Network
FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11
May 08, 2023
From
FSD Pharma Inc.
Via
Business Wire
Dynamic Duo of Celsius Holdings Fame join FSD Pharma calling Medical Product under Development “Unique and Disruptive”
April 19, 2023
Via
AB Newswire
Topics
Bankruptcy
Exposures
Financial
Legal
North America Could Possibly Emerge as the Market Leader for Billion Dollar Detox Drinks Industry
April 18, 2023
EQNX::TICKER_START (NASDAQ:CELH),(NASDAQ:OMER),(NYSE:MRK),(NASDAQ:RXDX) EQNX::TICKER_END
Via
FinancialNewsMedia
PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Completes Critical Step in Advancing Lucid-MS Pipeline
April 17, 2023
Via
Investor Brand Network
FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis
April 17, 2023
From
FSD Pharma Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.